sentence: FFAR2 selective antagonists that all showed to be inverse agonists by reducing constitutive activities of FFA2 receptors were described in a Euroscreen patent , with CATPB being the best characterized antagonist [ 94 ] , and later being described as structurally distinct in a high-throughput screening ( HTS ) campaign including 20,000 compounds ( Park et al. [ 95 ] ) .